DKK419.10
4.15% today
Copenhagen, May 16, 03:50 pm CET
ISIN
DK0060257814
Symbol
ZEAL
Sector
Industry

Zealand Pharma Target price 2025 - Analyst rating & recommendation

Zealand Pharma Classifications & Recommendation:

Buy
87%
Hold
13%

Zealand Pharma Price Target

Target Price DKK906.14
Price DKK402.40
Potential
Number of Estimates 14
14 Analysts have issued a price target Zealand Pharma 2026 . The average Zealand Pharma target price is DKK906.14. This is higher than the current stock price. The highest price target is
DKK1,120.00 178.33%
register free of charge
, the lowest is
DKK730.00 81.41%
register free of charge
.
A rating was issued by 15 analysts: 13 Analysts recommend Zealand Pharma to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Zealand Pharma stock has an average upside potential 2026 of . Most analysts recommend the Zealand Pharma stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million DKK 62.69 6,817.21
81.71% 10,774.48%
EBITDA Margin -1,983.12% 60.46%
1,175.58% 103.05%
Net Margin -1,831.24% 60.26%
613.83% 103.29%

14 Analysts have issued a sales forecast Zealand Pharma 2025 . The average Zealand Pharma sales estimate is

DKK6.8b
Unlock
. This is
12,141.36% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
DKK11.0b 19,619.88%
Unlock
, the lowest is
DKK8.7m 84.38%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 DKK62.7m 81.71%
2025
DKK6.8b 10,774.48%
Unlock
2026
DKK2.5b 63.93%
Unlock
2027
DKK2.8b 14.99%
Unlock
2028
DKK2.7b 4.09%
Unlock
2029
DKK5.1b 89.84%
Unlock

12 Analysts have issued an Zealand Pharma EBITDA forecast 2025. The average Zealand Pharma EBITDA estimate is

DKK4.1b
Unlock
. This is
400.09% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
DKK8.8b 740.04%
Unlock
, the lowest is
DKK-2.2b 58.51%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 DKK-1.2b 133.28%
2025
DKK4.1b 431.54%
Unlock
2026
DKK-46.8m 101.14%
Unlock
2027
DKK-332m 608.47%
Unlock
2028
DKK-185m 44.23%
Unlock
2029
DKK2.1b 1,259.32%
Unlock

EBITDA Margin

2024 -1,983.12% 1,175.58%
2025
60.46% 103.05%
Unlock
2026
-1.90% 103.14%
Unlock
2027
-11.73% 517.37%
Unlock
2028
-6.82% 41.86%
Unlock
2029
41.65% 710.70%
Unlock

10 Zealand Pharma Analysts have issued a net profit forecast 2025. The average Zealand Pharma net profit estimate is

DKK4.1b
Unlock
. This is
435.94% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
DKK9.1b 846.36%
Unlock
, the lowest is
DKK-2.1b 69.94%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 DKK-1.1b 30.55%
2025
DKK4.1b 457.87%
Unlock
2026
DKK-663m 116.14%
Unlock
2027
DKK-984m 48.30%
Unlock
2028
DKK-334m 66.08%
Unlock
2029
DKK776m 332.52%
Unlock

Net Margin

2024 -1,831.24% 613.83%
2025
60.26% 103.29%
Unlock
2026
-26.97% 144.76%
Unlock
2027
-34.78% 28.96%
Unlock
2028
-12.30% 64.63%
Unlock
2029
15.07% 222.52%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share DKK -16.24 58.12
30.55% 457.88%
P/E 6.92
EV/Sales 2.98

10 Analysts have issued a Zealand Pharma forecast for earnings per share. The average Zealand Pharma EPS is

DKK58.12
Unlock
. This is
435.95% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
DKK129.12 846.36%
Unlock
, the lowest is
DKK-29.40 69.94%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 DKK-16.24 30.55%
2025
DKK58.12 457.88%
Unlock
2026
DKK-9.38 116.14%
Unlock
2027
DKK-13.91 48.29%
Unlock
2028
DKK-4.72 66.07%
Unlock
2029
DKK10.98 332.63%
Unlock

P/E ratio

Current -23.26 55.77%
2025
6.92 129.75%
Unlock
2026
-42.89 719.80%
Unlock
2027
-28.92 32.57%
Unlock
2028
-85.25 194.78%
Unlock
2029
36.67 143.01%
Unlock

Based on analysts' sales estimates for 2025, the Zealand Pharma stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 364.47 216.85%
2025
2.98 99.18%
Unlock
2026
8.25 177.21%
Unlock
2027
7.18 13.03%
Unlock
2028
7.48 4.26%
Unlock
2029
3.94 47.32%
Unlock

P/S ratio

Current 510.81 327.64%
2025
4.17 99.18%
Unlock
2026
11.57 177.20%
Unlock
2027
10.06 13.03%
Unlock
2028
10.49 4.26%
Unlock
2029
5.52 47.32%
Unlock

Current Zealand Pharma Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
BERENBERG
Locked
Locked
Locked Mar 31 2025
CANTOR FITZGERALD
Locked
Locked
Locked Mar 31 2025
KBC SECURITIES
Locked
Locked
Locked Mar 24 2025
BTIG
Locked
Locked
Locked Mar 17 2025
DNB MARKETS
Locked
Locked
Locked Mar 13 2025
JEFFERIES
Locked
Locked
Locked Mar 11 2025
WILLIAM BLAIR & COMPANY
Locked
Locked
Locked Mar 11 2025
Analyst Rating Date
Locked
BERENBERG:
Locked
Locked
Mar 31 2025
Locked
CANTOR FITZGERALD:
Locked
Locked
Mar 31 2025
Locked
KBC SECURITIES:
Locked
Locked
Mar 24 2025
Locked
BTIG:
Locked
Locked
Mar 17 2025
Locked
DNB MARKETS:
Locked
Locked
Mar 13 2025
Locked
JEFFERIES:
Locked
Locked
Mar 11 2025
Locked
WILLIAM BLAIR & COMPANY:
Locked
Locked
Mar 11 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today